Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

<div>Mean ± standard deviation atazanavir plasma concentration-time curves after administration of atazanavir/ritonavir 300/100 mg qd for two weeks in combination with two NRTIs (Day −1), followed by administration of etravirine 200 mg bid for two weeks in combination with one NRTI and (a) atazanavir/ritonavir 300/100 mg qd or (b) atazanavir/ritonavir 400/100 mg qd (Week 2). ATV/r: atazanavir/ritonavir; bid: twice daily; ETR: etravirine; NRTI: nucleoside reverse transcriptase inhibitor; qd: once daily.</div>

AIDS Research and Treatment

fig3

Figure 3

Figure 3: Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients 

Figure 3 | Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients 